Regulatory approval

Published by the Health Service Executive.

The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab 1200mg as a monotherapy for reimbursement as a treatment option for the adjuvant treatment following complete resection and platinum-baesd chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumors have PD-L1 expression on >= 50% of tumor cells and who do not have EGFR mutant or ALK-positive mutations.

This is written in the approval document as:

Adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with non-small cell lung cancer (NSCLC) with a high risk of recurrence whose tumours have PD-L1 expression on >= 50% of tumour cells and who do not have EGFR mutant or ALK-positive mutations.

Citation

Atezolizumab Monotherapy, 2024, version number 13, NCCP National SACT Regimen, NCCP, viewed 01/09/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	PD-L1 >= 50%, Wild type ALK, Wild type EGFR	Non-Small Cell Lung Cancer	Atezolizumab